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Cefuroxime axetil (CA) is an ester prodrug of cefuroxime with an unpleasant taste when
administrated orally. This work was to mask the bitter taste of CA and enhance its oral
bioavailability. Dry suspensions were prepared by means of wet granulation method and
solid dispersion method. Binders, suspending agents and other compositions involved in
the formulation were optimized. The differential scanning calorimetry (DSC) analysis
indicated that CA was amorphous in the solid dispersion with stearic acid as the carrier,
which contributed to an improvement of the dissolution rate. Taste evaluation was per-
formed by three volunteers and taste masking was successfully achieved by the methods
mentioned above. A pH 7.0 phosphate buffer was adopted to study the in vitro dissolution
performance of the three formulations, i.e., two self-made dry suspensions and the com-
mercial one. With a better release characteristic and a satisfying taste masking ability, the
solid dispersion suspension was selected as the optimal formulation for the further
pharmacokinetic study in beagle dogs. The values of Cmax and AUC0e12 for the solid
dispersion suspension were about 1.78-fold and 2.17-fold higher than these of reference
suspension, respectively. The obtained results demonstrated that the solid dispersion can
efficiently mask the bitter taste of CA and significantly enhance its oral bioavailability.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
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loxyethyl ester modification, the prodrug CA displays anti-
bacterial activity in oral delivery [1,2]. After oral administra-
tion, CA is absorbed, and then rapidly hydrolyzed by the non-
specific esterases which is distributed in the intestinal mu-
cosa and portal blood, and ultimately transformed into the
pharmacological active molecule cefuroxime [3]. The chemi-
cal structure of CA is shown in Fig. 1. The esterification has no
impact on the antibacterial efficiency of cefuroxime. But like
other water-insoluble drugs, CA has a limited solubility and
dissolution rate in the gastrointestinal tract [4,5]. Further-
more, CA has an unpleasant taste which is likely to result in
poor patient compliance, especially in the case of children and
infants. Hence, taste masking and improving oral bioavail-
ability are the key issues in the present work.
Oral administration is preferred among the various drug
delivery systems, due to these advantages, such as safety,
convenience, good patient compliance and so on. However,
for themedicinal agents having unpleasant taste, oral delivery
tends to be unfavorable. It is reported that the bitter sub-
stances interact with the taste buds and thus causing a
negative sensory response [6]. Besides the conventional
incorporation of flavors and sweeteners, there have been
various approaches to solve this problem by employing
various of dosage platforms such as fast dissolving platform,
physical barriers, chemical or soluble modification and solid
dispersion technology [6,7]. Among the above methods, solid
dispersion gains great interest because it cannot only mask
the bitter taste, but also enhance the dissolution rate for
water-insoluble drug and consequently increase the oral
bioavailability [8].
The commercial formulations available now include tablet,
capsules, dispersible tablet and granules. In this work, we
attempt to develop a taste masked dosage form of CA by
employing dry suspension. Oral suspension is preferred to
many patients because of the ease of swallowing and the
flexibility in the administration. It is particularly advanta-
geous for children, the elderly and infants, in the meantime,
the unpleasant taste of the bitter medicinal agents can be
overcome by administrating as undissolved particles. Dry
powders for suspension aremore desired due to their stability
and convenience [9].
Dry suspension of CA was well prepared with wet granu-
lation method and solid dispersion method in the present
work. A simple and most used method for the preparation of
solid dispersion, melting method [8] was adopted to prepare
the solid dispersion. The in vitro and in vivo characteristics ofFig. 1 e The chemical structure of cefuroxime axetil.the two self-made dry suspensions and its commercial
formulation were evaluated.2. Materials and methods
2.1. Materials
Cefuroxime axetil and the cefuroxime axetil commercial dry
suspension (Yuntai, NO. 20100503) were purchased from
Shandong Lukang Pharmaceutical Group Co., Ltd. (China).
Micronization silica gel, orange flavor concentration were
purchased from Beijing Fengli Jingqiu Commerce and Trade
Co., Ltd. (China). PVP K30 and microcrystalline cellulose were
kindly supplied by BASF Co., Ltd. (Shanghai, China) and Anhui
Sunhere Pharmaceutical Excipients Co., Ltd. (China), respec-
tively. Stearic acid and HPMC E5were purchased fromHuzhou
Zhanwang Pharmaceutical Factory (China). Pregelatine starch
was purchased from Shanxi Huaqi Commerce and Trade Co.,
Ltd. (China). Xanthan gum was purchased from Deosen
Biochemical, Ltd. (Shandong, China). Xylitol was purchased
from Futaste Co., Ltd. (Shandong, China). Aspartame was
purchased from Changzhou Niutang Chemical Co., Ltd.
(China). Acesulfame potassium was purchased from Beijing
Weiduo Chemical Co., Ltd. (China). PEG6000 was purchased
from Tianjin Kermel Chemical Reagent Co. Ltd. (Tianjin,
China). Methanol and acetonitrile of chromatographic grade
were purchased from Concord Technology Co., Ltd. (Tianjin,
China). Cefuroxime Standard (91.6%, NO. 130943e200704) and
glimepiride Reference Standard (99.9%) were purchased from
National institutes for food and drug control. Deionized-
distilled water was used throughout this study.2.2. Preparation of cefuroxime axetil suspension by wet
granulation method
Accurately weighed amounts of cefuroxime axetil and
micronization silica gel (passed through 100-mesh sieve,
respectively) were mixed together until uniform. Certain
amounts of PVP K30, pregelatinized starch and powdered su-
crose according to the formular were prepared in the same
way. After the two mixtures being blended homogeneous, a
liquid binder was added to facilitate the powder particles
adhesion and prepared the damp mass. The resultant wet
mass was screened into granules through a 60-mesh sieve,
and then be dried in thermostatically controlled oven at 60 C.
After drying, the granules were sized by passing through a 60-
mesh screen. Other excipients including microcrystalline
cellulose, xylitol, aspartame, acesulfame potassium, and or-
ange flavor concentrate were passed through a 80-mesh
screen and mixed well with the prepared granulation. The
final dry suspension was sub-packaged for further evaluation.2.3. Optimization of binders and suspending agents
Different concentration of PVP K30 and hydrox-
ypropylmethylcellulose (3%, 5%, 10%) as binders both in
aqueous and alcohol solution were investigated when pre-
paring the wet damp mass. Optimal binder and the proper
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ticle size uniformity.
Suspending agent was optimized using single factor
method. Arabic gum, xanthan gum, sodium alginate and
hydroxypropylmethylcellulose were investigated for the
ability of suspending using relative sediment volume as the
evaluation index.
2.4. Preparation of cefuroxime axetil suspension by solid
dispersion method
A melting method was adopted to prepare the solid disper-
sion. Firstly, accurately weighted amounts of 12.5 g CA and
proper sucrose (1, 1.5, 2 times relative to the weight of CA)
were passed through a 100-mesh screen and mixed. Carriers
were heated at 70 C to melt entirely, then the mixture of CA
and sucrose were slowly added to the carriers with stirring
until dissolved. After totally dispersed, the resultant mixture
was quickly poured into the precooled evaporation pan, and
then cooled in an ice bath under stirring to form a solid
dispersion for another 1 h. After dried in thermostatically
controlled oven to constant weight, the solid were pulverized
and passed through a 40-mesh screen and then a 80-mesh
screen, particles with diameters between the two sizes were
selected for further use. PEG6000, arabic gum, Poloxamer 188,
stearic acid and glyceryl monostearate were evaluated, and a
series of solid dispersion were prepared with the final drug-
carrier weight ratio of 1:4, 1:5 and 1:6. Other excipients
including powdered sucrose, xylitol, aspartame, acesulfame
potassium, xanthan gum, and orange flavor concentrate were
passed through a 80-mesh screen and mixed well with the
prepared solid dispersion powders. The final dry suspension
was sub-packaged for further evaluation.
2.5. Differential scanning calorimetry analysis
The thermal properties of stearic acid, raw cefuroxime axetil,
powdered sucrose, physical mixture, and the solid dispersion
of the three substances were characterized using a differential
scanning calorimetry (DSC 60, Shimadzu) instrument. Sam-
ples each weighing 10 mg were placed in hermetical
aluminum pans, with Al2O3 as a reference. The temperature
increased with a heating rate of 10 C/min from 30 C to 250 C
under a nitrogen gas flow.
2.6. Quality control
2.6.1. Physicochemical properties of the suspensions
The physical properties of the two dry suspensions made by
different methods were evaluated after reconstitution,
including color, pH, relative sediment volume, redispersibility
and viscosity. Taste evaluation was performed by oral
administration of the reconstituted suspensions to identify
whether the formulations were taste masked, and three vol-
unteers were involved in this experiment. Formulations were
classified into four degrees: 1. Tasteless, or taste masked; 2.
Slightly bitter, or accepted taste; 3. Bitter; 4. Very bitter. The
raw CA was used as the reference with intervals of 2 h during
each experiment, and volunteers were supplied with suffi-
cient drinking water [10,11].2.6.2. Assay of the drug content
The content of CA in the suspensions was determined by
using a HPLC method. The HPLC system was equipped with a
LC-10A VP HPLC pump and a SPD-10A VP UVeVIS detector. A
VP-ODS C18 column (5 mm, 150  4.6 mm) was used with a
mobile phase of methanolewater (40:60, v/v) at a flow rate of
1 ml/min. The UV detector was operated at 278 nm, and the
retention time of CA was 12.6 min.
Solutions of dry suspensions and the CA Standard were
prepared at a concentration of about 0.1 mg/ml of CA with
methanol as the solvent, respectively. Perform the test with
20 ml of the two solutions. The content was calculated by the
external standard method.
2.6.3. Primary stability study of the suspensions
Primary stability study of the suspensions was investigated at
temperatures of 40 C and 60 C, at relative humidities of 75%
and 92.5%, and exposed to light of 4500 lx for 5 d and 10 d.
2.7. In vitro dissolution tests
In vitro dissolution behaviors of the two kinds of CA dry sus-
pensions and its commercial dry suspension were investi-
gated using a ChP2010 Type2 dissolution apparatus (paddle
method), and all the tests were carried out in triplicate. A
volume of 900 ml pH 7.0 phosphate buffer was used as the
release medium and the temperature was maintained at
37  0.5 C with a paddle speed of 50 r/min. A certain amount
of dry suspensions equivalent to 125mg CAwere used in all of
the dissolution tests. At pre-determined time intervals (5, 10,
20, 30, 45, 60 min), an aliquot of 5 ml of the release medium
was withdrawn and passed through a 0.22 mm filter immedi-
ately. An equal volume of fresh medium was replaced. The
concentration of CA in filtrate was determined using a UV
spectrophotometer (Beijing Rayleigh Analytical Instrument
Co.) at 280 nm.
2.8. Pharmacokinetic study in beagle dogs
2.8.1. Animals and dosing
The pharmacokinetic tests were in accordance with the Guide
for Care and Use of Laboratory Animals of Shenyang Phar-
maceutical University. Six male beagle dogs weighing
12e18 kg were used and were randomly divided into two
groups. A cross-over design was adopted with a washout
period of seven days. All of six dogs were fasted overnight for
12 h with free access to water. The solid dispersion dry sus-
pension and the commercial dry suspension were adminis-
trated orally at a single dose equivalent of 125 mg of CA. 3 ml
of venous blood were collected from the dog’s foreleg after
oral administration at pre-determined time intervals (pre-
dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10 and 12 h post dose).
The plasma was separated from the blood sample immedi-
ately by centrifuging at 3500 r/min for 10 min and stored at
20 C until analysis.
2.8.2. Determination of cefuroxime in plasma
The concentration of cefuroxime in plasma was determined
by a validated HPLCeMS/MS method with glimepiride as the
internal standard. A solid phase extraction was employed
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mixture of methanolewater (50:50, v/v) and 50 ml internal
standard solution were added to 200 ml plasma, the mixture
was mixed for 2 min before a centrifugation of 10 min at
13,000 r/min. The supernatant was then loaded on a solid
phase extraction column (preconditioned with 1 ml of meth-
anol and then 1 ml of ultrapure water). After washing by 2 ml
of water twice, the analytes were eluted by 2 ml methanol.
Then the eluent was evaporated to dryness under a nitrogen
flow and then be reconstituted by 100 ml mobile phase. 10 ml of
the sample was used for analysis. The chromatographic sep-
arations were carried out on an ACQUITY UPLCTM system
(Waters Corp., Milford, MA) and BEH C18 column
(50 mm  2.1 mm, 1.7 mm; Waters Corp.) using acetonitrile-
5 mM ammonium acetateeformic acid (60:40:0.01) as the
mobile phase with a flow rate of 0.2 ml/min. The compounds
were analyzed by multiple reaction monitoring (MRM) of the
transitions of m/z 423 / 207 for cefuroxime and m/z
491.13/ 352.24 for glimepiride, respectively.
2.8.3. Data analysis
The maximum plasma concentration of cefuroxime (Cmax)
and the time to reach Cmax (Tmax) were noted directly from the
drug concentrationetime profiles. The pharmacokinetic pa-
rameters such as area under curve (AUC), and the half life of
the preparation (T1/2) were calculated by DAS 2.1 software
using a noncompartmental model. All data were shown as
their mean S.D. (standard deviation). The t-test was used for
statistical analysis, and the differences were considered sig-
nificant at p < 0.05. The relative bioavailability value (F) was
calculated using the following formula with the commercial
dry suspension as a reference:
Fr ¼ ðAUC0tÞTðAUC0tÞR
 100%3. Results and discussion
3.1. Preparation of cefuroxime axetil suspension
In the present study, we prepared two formulations to mask
the unpleasant taste of CA, i.e., the wet granulation dry sus-
pension and solid dispersion dry suspension. In the wet
granulation method, the porous carrier micronization silica
gel can sufficiently decrease the drug concentration in mouth
cavity and prevent the CA from precipitating by a mechanism
of absorption. Polymers were also added to the dry suspen-
sions, which made the suspension viscous after hydration.
The thick liquid restrained the drug molecular from diffusing
to interact with the taste buds. Solid dispersion also plays an
important role in taste masking technology except itsTable 1 e The relative sediment volume of suspensions made
Suspending agents Arabic gum Xanthan gum
Relative sediment volume 96.8%  0.76% 100%remarkable achievements in improving the dissolution and
bioavailability of water-insoluble drugs [8].
3.1.1. Effect of different binders
In the process of preparing the damp mass, different con-
centrations of PVP K30 and hydroxypropylmethylcellulose
(3%, 5%, 10%) as binder, in their aqueous and alcohol solutions
were investigated by judging the optimal binder from the
granule hardness and the particle size uniformity. A liquid
binder is often added to facilitate the powder particles adhe-
sion and prepared the dampmass in wet granulationmethod.
The binding agents usually used are 10e20% corn starch
aqueous preparation, povidone, 25e50% glucose solution, 3%
methylcellulose, PVP K30, hydroxypropylmethylcellulose and
so on. A good binder results in proper granule hardness and
don’t impact on the drug dissolution. For these reasons we
choose three different concentrations of the two binders both
in there aqueous and alcohol solution. The amounts of the
binders used are according to the practice experience, i.e., the
resultant wet mass should be squeezed in the hand. If the
granules are too hard, it would be difficult for the loading drug
to release, in contrast, if they are too soft, the granules tend to
be crush causing the particles break into fine powders and
have a wide range of particle size distribution. An alcohol
preparation of PVP K30 (5%)was selected as the optimal binder
after experiments for it offering the granules appropriate
hardness and a narrow range of particle size distribution.
3.1.2. Influence of different suspending agents
A suspending agent is needed in the dry suspension system in
the case of reconstitution. Upon dilution and agitation with a
specified quantity of vehicle, the dispersed particles have a
tendency to settle to the bottom of the container because they
have a greater density then that of the dispersion medium.
According to the equation of Stocks’ law, an increase of the
viscosity of the dispersion medium can decrease the rate of
particle sedimentation. By adding suspending agent to the dry
suspension, we can expect a slower rate of descent of the
particles when the dry powders of suspension are recon-
stituted. In this study, arabic gum, xanthan gum, sodium
alginate and hydroxypropylmethylcellulose were investigated
for the ability of suspending using relative sediment volume
as the evaluation index. The relative sediment volume was
shown in Table 1. The nonionic polymer, xanthan gum can be
completely absorbed on the particles as a hydrodynamic layer
to prevent the aggregation and settlement due to steric hin-
drance between the particles and make the suspension easily
redispersed. Meanwhile, the polymer restrained the drug
diffusion hence exerting a synergistic effect on taste masking.
So xanthan gum was selected as the optimal suspending
agent for its excellent suspending ability in all the experi-
ments. The final formula of wet granulation was shown in
Table 2.up of different suspending agents.
Sodium alginate Hydroxypropylmethylcellulose
92.0%  1.0% 95.7%  0.58%
Fig. 2 e The DSC curves of stearic acid, pure cefuroxime
axetil, powdered sucrose, physical mixture and the solid
suspension of the three substances.
Table 2 e Formulation of dry suspension by wet
granulation method.
Ingredients Quantity (%)
Cefuroxime axetil 10.00
Micronization silica gel 8.00
PVP K30 10.00
Pregelatine starch 10.00
Sucrose 25.00
Microcrystalline cellulose 11.00
Xylitol 12.00
Xanthan gum 8.00
Aspartame 3.00
Acesulfame potassium 2.00
Orange flavor concentrate 1.00
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Solid dispersion is a process in which drugs distributed or
dispersed throughout a solid carrier. It used to be a widely
accepted platform in the field of taste masking. Several
methods have been developed to prepare solid dispersion
such as melting method, hot melt extrusion, solvent evap-
oration method, spray drying, supercritical fluid precipita-
tion and so on [14,15]. We choose the simple melting method
in this work. In the process, the active medicinal substance
is allowed to be dissolved or dispersed in the melted solid
carriers. Through cooling and pulverizing the molten
mixture we can get the solidified granules. Five classic
polymers having a low melting point including PEG6000,
arabic gum, Poloxamer 188, stearic acid and glyceryl mono-
stearate were investigated in the experiment. Upon the
addition of CA, the clear and transparent molten carriers
became yellow in terms of PEG6000, arabic gum and Polox-
amer 188 which indicated a potential change in physico-
chemical characteristics. Although glyceryl monostearate
didn’t undergo a color transformation, it produced a
disgusting smell. Therefore, stearic acid was selected as the
optimal carrier and final drug-carrier weight ratios of 1:4, 1:5
and 1:6 were evaluated. To further strengthening the taste
masking ability and accelerating the drug release from the
lipophilic stearic acid, sucrose, a water-soluble sweetener
was added to the drug-carrier mixture. Overall, when CA,
sucrose, stearic acid mixed at a weight ratio of 1:2:4, the
resulting powders had a good dispersibility and showed
excellent taste masking ability. The optimal formula was
shown in Table 3.Table 3 e Formulation of dry suspension by solid
dispersion method.
Ingredients Quantity (%)
CAeSucroseeStearic-acid solid dispersion
(1:2:4, w/w/w)
70.00
Sucrose 12.00
Xylitol 6.00
Aspartame 2.00
Acesulfame potassium 3.00
Xanthan gum 6.00
Orange flavor concentrate 1.003.2. Differential scanning calorimetry analysis
DSC curves of stearic acid, raw cefuroxime axetil, powdered
sucrose, the physical mixture, and the solid dispersion were
shown in Fig. 2. As can be seen from the curves, the raw
cefuroxime axetil showed decalescence peaks and themelting
points were about 86.68 C and 179.01 C, which indicates the
pure drug was polymorphs. The stearic acid and powdered
sucrose showed endothermic peaks at 61.37 C and 185.40 C,
respectively. The physical mixture just showed the above four
decalescence peaks. In the curve of the solid dispersion, the
two endothermic peaks of stearic acid and powdered sucrose
can be easily identified while the endothermic peaks of CA
disappeared totally, indicating that CA was amorphous
incorporated in solid dispersion and powdered sucrose was
not incorporated in solid dispersion for its hydrophilicity.3.3. Physicochemical properties of the suspension
Physicochemical properties of the self-made dry suspensions
after reconstitution including color, pH, relative sediment
volume, redispersibility, viscosity and drug loading were
evaluated for quality control. All the properties generally met
the requirements for suspension and all the evaluation pa-
rameters were shown in Table 4. When the dry suspensionsTable 4 e Physicochemical properties of the suspensions.
Properties Formulation 1a Formulation 2b
Color White White
pH 5.60  0.02 5.24  0.02
Viscosity Very low Very low
Redispersibility Quite easy Quite easy
Relative sediment volume 100.0% 100.0%
Drug content 99.13  0.64 99.02  0.34
Taste evaluation First rank First rank
a Formulation 1 is referred to solid dispersion suspension.
b Formulation 2 is referred to wet granulation suspension.
Table 5 e Primary stability of the suspensions.
Storage
conditions
Formulation 1a Formulation 2b
Appearance Content
(%)
pH Weight
gain
(%)
Appearance Content
(%)
pH Weight
gain
(%)
Beginning White powder 100.41  0.02 5.60  0.31 0 White powder 99.9  0.34 5.24  0.02 0
40 C
5 d White powder 101.72  0.78 5.55  0.54 e White powder 100.22  0.37 5.10  0.51 e
10 d White powder 96.93  0.66 5.55  0.32 e White powder 98.41  0.98 5.13  0.20 e
60 C
5 d Light yellow powder 96.50  0.65 4.46  0.20 e Light yellow powder 94.21  0.46 4.51  0.03 e
10 d Light yellow powder 96.11  0.36 4.22  0.37 e Yellow powder 93.32  0.88 4.32  0.15 e
RH75%
5 d White powder 99.83  0.78 5.57  0.43 0.97  0.71 White powder 98.43  0.91 5.07  0.08 1.21  0.03
10 d White powder 98.32  0.69 5.54  0.89 1.03  0.04 White powder 97.67  1.01 5.00  0.10 1.78  0.35
RH92.5%
5 d White powder 99.10  0.44 5.41  0.91 2.65  0.21 White powder 97.68  1.22 5.14  0.31 3.05  0.18
10 d White powder 95.75  1.03 5.14  0.65 5.19  0.63 White powder 96.54  0.93 5.07  0.11 6.11  0.36
4500 lx
5 d White powder 100.32  1.22 5.63  0.66 e White powder 99.52  0.67 5.20  0.20 e
10 d White powder 98.10  1.09 5.64  0.59 e White powder 97.21  0.90 5.20  0.07 e
a Formulation 1 is referred to solid dispersion suspension.
b Formulation 2 is referred to wet granulation suspension.
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color and a good redispersibility with no sedimentation during
24 h. The relative sediment volumewas calculated by the ratio
of the volume after sedimentation and the original volume.
The higher the value is, the more stable the suspension will
be. The suspensions showed a very low viscosity which also
benefits to the redispersion, and the drug loading test revealed
that the suspension had a drug content of 99.02  0.34% and
99.13  0.64% for wet granulation suspension and solid
dispersion suspension, respectively.0
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Fig. 3 e Dissolution profiles of two formulations of
cefuroxime axetil dry suspension and its commercial dry
suspension in pH 7.0 phosphate buffer (means ± SD, n[ 3,
Formulation 1: Solid dispersion suspension; Formulation
2: Wet granulation suspension).For oral drug delivery system, taste is an important issue
for the administration of bitter drugs. Solving this problem is
the main purpose of this study. Taste evaluation was per-
formed by oral administration of the reconstituted suspen-
sions, and three volunteers were involved in this experiment.
The results showed that each volunteer classified the two
self-made formulations to the first rank, while the raw CA
was belonging to the third rank. Taste evaluation indicates
that the taste of CA was successfully masked by both
formulations.0
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Fig. 4 e Average drug concentrationetime profiles after a
single oral dose of cefuroxime axetil dry suspension and
the reference suspension (means ± SD, n [ 6).
Table 6 e Pharmacokinetic parameters of test and reference preparations.
T1/2 (h) Cmax (ng/ml) Tmax (h) AUC0e12 (ng h/ml) AUC0eN (ng h/ml) F (%)
Reference 1.9  0.9 2825.6  2683.8 2.1  1.2 6866.7  3749.7 7136.7  3727.4 100.0
Test 1.6  0.5 5017.5  2273.6 1.7  1.3 14892.5  6740.2 15039.7  6719.3 274.0  188.9
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drug content, pH and weight gain (%) were investigated. Ac-
cording to the results shown in Table 5, both of the formula-
tions showed a decreased pH under the high temperature of
60 C, and a slight weight gain under the high relative hu-
midity of 70% and 92.5%. So the samples used in the current
experiment were stored in sealed containers away from heat,
light and humidity to keep its properties unchanged.
3.4. In vitro dissolution test
The dissolution of commercial dry suspension and dry sus-
pensions prepared by wet granulation method and solid
dispersionmethodwere performed in pH 7.0 phosphate buffer
and the corresponding profiles are shown in Fig. 3. Both for-
mulations showed a higher and faster release than that of the
commercial suspension. The solid dispersion suspension
displayed a significant improvement in dissolution rate with
more than 70% of the drug dissolved within 20 min, owing to
the amorphous state of drug in the solid dispersion. In com-
parison with the self-made formulations, the commercial dry
suspension showed a lower and slower release, and only
around 50% of the drug dissolved within 20 min.
3.5. Pharmacokinetic study
A sensitive and accurate liquid chromatographyedual mass
spectrometry analysis method and a solid phase extraction
process were well validated. The in vivo pharmacokinetic be-
haviors of solid dispersion suspension and commercial dry
suspension were investigated following a single oral dose of
125 mg CA to six beagle dogs. The mean drug concen-
trationetime profiles of the test and reference formulations
are presented in Fig. 4. Themain pharmacokinetic parameters
are listed in Table 6. The Cmax and AUC0e12 values of the solid
dispersion suspension were about 1.78-fold and 2.17-fold
greater than these of the reference suspension with signifi-
cant difference, respectively. The Tmax decreases by half an
hour, which indicated a rapid dissolution and absorption of
the drug, but there were no significant difference between the
Tmax of the two formulations. The relative bioavailability (F) of
test formulationwas 274.0 188.9%,which illustrated that the
test formulation can improve the oral bioavailability signifi-
cantly compared with the reference suspension.
Bioavailability refers to the rate and amount of a drug
entering the systemic circulation after administration, and
the bioavailability of the intravenous route of administration
was considered to be 100%. For other routes of drug delivery,
bioavailability was determined by drug solubility and perme-
ability, and many other diverse factors involved in the
manufacturing process, such as particle size, crystal form,
physicochemical properties of excipients. For drugs with poor
dissolution and limited permeability, their bioavailability is
often incomplete [14]. The enhanced oral bioavailability of theself-made solid dispersion suspension is probably attributed
to the amorphous state of CA in solid dispersion, making the
loading drug dissolved and absorbed more effectively in the
gastrointestinal tract. The same result was obtained in other
research that the bioavailability was improved after admin-
istration of amorphous CA in nanoparticles [16]. Drugs are
observed amorphous when they are prepared into solid
dispersion, and they can be incorporated at a molecular level
or as the particles throughout the carriers. The particles
dispersed in the solid dispersion are usually at a nanoscopic
level [17,18], which results in an increased dissolution rate
according to the NoyeseWhitney equation. Moreover, the
amorphous drug has a higher apparent solubility than the
crystalline form [19]. And more importantly, the amorphous
form didn’t undergo crystal transition and showed sufficient
stability for a long time, which is essential for transportation
and storage of the pharmaceutical dosage forms [20]. In this
regard, we can better understand why solid dispersion sus-
pension had a significant improvement of the oral
bioavailability.4. Conclusion
Taste masked dry suspensions of a bitter drug, cefuroxime
axetil, were successfully prepared using wet granulation
method and solid dispersion method. Several important pa-
rameters involved in the formulation procedure were opti-
mized. The DSC analysis indicated that CA was amorphous in
the solid dispersion, resulting in an enhancement of the
dissolution rate and extent. As the optimal formulation, the
solid dispersion suspension was selected for the further
pharmacokinetic study in beagle dogs. The Cmax and AUC0e12
values of the solid dispersion suspension were about 1.78-fold
and 2.17-fold greater than these of reference suspension,
respectively. The obtained results demonstrated that the solid
dispersion suspension can efficiently mask the bitter taste of
CA and significantly enhance its oral bioavailability.
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